Skip to main content

Table 1 Demographic and clinical features of patients from both the Israeli and the US cohorts upon presentation

From: Do geography and ethnicity play a role in juvenile Spondyloarthritis? A multi-center binational retrospective study

Characteristic All subjects (n = 87) Israeli cohort (n = 39) US cohort (n = 48) P value*
Demographics, mean (SD) or n (%)
 Sex, male 58 (66.7) 22 (56.4) 36 (75) 0.11
 Race, Caucasian 58/78 (74.3) 29/31 (93.5) 29/47 (61.7) 0.001
 Age at symptom onset in years 11.6 (2.6) 12.3 (2.6) 10.9 (2.5) 0.01
 Age at diagnosis in years 13 (2.8) 14.3 (2.7) 11.9 (2.5) < 0.001
 FHx of HLA-B27-associated disease (FDR) 7 (8) 2 (5.1) 5 (10.4) 0.45
Clinical characteristics, n (%)
 Back pain 40 (46) 23 (59) 17 (35.4) 0.033
 Sacroiliac tenderness 27 (31) 19 (48.7) 8 (16.7) 0.002
 Positive modified Schober test 13/65 (20) 7/17 (41.2) 6 (21.5) 0.029
 Positive FABER test 12/66 (18.2) 6/18 (33.3) 6 (12.5) 0.07
 Enthesitis 22 (25.3) 3 (7.7) 19 (39.6) 0.001
 Peripheral arthritis 61 (70.1) 17 (43.6) 44 (91.7) < 0.001
 Arthritis in a male over 6 years old 58 (66.7) 22 (56.4) 36 (75) 0.11
 Acute symptomatic uveitis 3 (3.4) 0 (0) 3 (6.2) 0.25
 HLA-B27 positivity 40/70 (54.8) 8/25 (32) 32 (66.7) 0.007
 ANA- positive 19/73 (26) 10/28 (35.7) 9/45 (20) 0.17
 CRP, elevated 36/74 (48.6) 17/30 (56.7) 19/44 (43.2) 0.34
 ESR, elevated 30/62 (48.4) 9/17 (52.9) 21/45 (46.7) 0.78
 MRI defined Sacroiliitis 40/67 (59.7) 29/30 (96.7) 11/37 (29.7) < 0.001
Treatment before or at time of diagnosis, n (%)
 NSAIDs 72 (82.8) 27 (69.2) 45 (93.7) 0.004
 DMARDs (sulfasalazine or methotrexate) 12 (13.8) 8 (20.5) 4 (8.3) 0.13
 Biologics 7 (8) 3 (7.7) 4 (8.3) 1
  1. *P-value of < 0.05 is considered statistically significant. SD Standard deviation, IL Israel, FHx family history, HLA Human leukocyte antigen, FDR first degree relative, FABER Flexion Abduction External Rotation, ANA Antinuclear antibody, CRP C-reactive protein, ESR Erythrocyte sedimentation rate, MRI Magnetic resonance imaging